Pasithea Therapeutics
KTTA
11 hedge funds and large institutions have $148K invested in Pasithea Therapeutics in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 11 → 11 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.04% less ownership
Funds ownership: 0.11% → 0.07% (-0.04%)
64% less capital invested
Capital invested by funds: $406K → $148K (-$258K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$17.5K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$14.2K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$6.43K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$181K |
| 2 |
VF
Virtu Financial
New York
|
-$9.09K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$8.15K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.38K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$23 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $60.1K | – | – | – |
|
2
Geode Capital Management
Boston,
Massachusetts
| $38.2K | – | – | – |
|
|
3
Renaissance Technologies
New York
| $12K | +$17.5K | +1,550 | New |
|
|
4
Citadel Advisors
Miami,
Florida
| $9.75K | +$14.2K | +1,253 | New |
|
5
State Street
Boston,
Massachusetts
| $9.2K | – | – | – |
|
|
VF
6
Virtu Financial
New York
| $6K | -$9.09K | -804 | -52% |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $5K | -$1.38K | -122 | -16% |
|
|
8
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $4.42K | +$6.43K | +569 | New |
|
9
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | – | – | – |
|
10
JP Morgan Chase
New York
| $1K | – | – | – |
|
11
Wells Fargo
San Francisco,
California
| $48 | – | – | – |
|
|
12
Bank of America
Charlotte,
North Carolina
| $3 | -$23 | -2 | Closed |
|
|
KPF
13
K2 Principal Fund
Toronto,
Ontario, Canada
| – | -$181K | -14,122 | Closed |
|
|
14
UBS Group
Zurich,
Switzerland
| – | -$8.15K | -637 | Closed |
|
KTTA Hedge Fund Activity: Q1 2023 in Review
11 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q1 2023, worth a combined $148K — down 64% from $406K a quarter earlier.
Fund positioning in KTTA was balanced in Q1 2023: 3 funds opened new positions, 3 closed out, 0 added to existing stakes and 2 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $17.5K. The largest seller was K2 Principal Fund, exiting entirely with an estimated $181K sold.
- 11 institutional investors held Pasithea Therapeutics (KTTA) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $148K of Pasithea Therapeutics stock for Q1 2023, down 64% quarter-over-quarter.
- 3 funds opened new Pasithea Therapeutics positions in Q1 2023 and 3 closed out, a net change of 0 holders.
- The largest Pasithea Therapeutics buyer in Q1 2023 was Renaissance Technologies, an estimated $17.5K added.
- The largest Pasithea Therapeutics seller in Q1 2023 was K2 Principal Fund, an estimated $181K sold.
Based on aggregated 13F filings for Q1 2023.